Otsuka Pharmaceutical Co. v. Lupin Ltd. (Fed. Cir. 2026)
In a nonprecedential decision, the Federal Circuit recently affirmed a district court’s finding that innovator drugmaker Otsuka Pharmaceutical failed to show generic competitor Lupin infringed (or would infringe, if it marketed an FDA-approved generic …